GlaxoSmithKline
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Established
- 1929-01-01
- Employees
- 70.2K
- Market Cap
- $90B
- Website
- http://www.gsk.com
- Introduction
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.
Study to Show That the Combined Hepatitis A and B Vaccine is Non-inferior to Monovalent Vaccines in Adults
- Conditions
- Hepatitis BHepatitis A
- First Posted Date
- 2008-01-29
- Last Posted Date
- 2017-03-14
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 213
- Registration Number
- NCT00603252
- Locations
- 🇩🇪
GSK Investigational Site, Elmshorn, Schleswig-Holstein, Germany
Immunogenicity and Safety of a Candidate Tuberculosis (TB) Vaccine Given to Healthy Adults in a TB-endemic Region
- Conditions
- Tuberculosis (TB)Tuberculosis Vaccines
- Interventions
- Biological: GSK Biologicals' Candidate Tuberculosis (TB) Vaccine (692342)
- First Posted Date
- 2008-01-25
- Last Posted Date
- 2020-10-12
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 45
- Registration Number
- NCT00600782
- Locations
- 🇿🇦
GSK Investigational Site, Worcester, Western Province, South Africa
Study Of An NK-1 Anti-Emetic Medication For The Prevention Of Post-Operative Nausea And Vomiting In Female Patients
- Conditions
- Postoperative Nausea and VomitingNausea and Vomiting, Postoperative
- First Posted Date
- 2008-01-25
- Last Posted Date
- 2017-01-20
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 624
- Registration Number
- NCT00600990
- Locations
- 🇬🇧
GSK Investigational Site, Northampton, Northamptonshire, United Kingdom
A Study Of IV Casopitant For The Prevention Of Chemotherapy Induced Nausea And Vomiting.
- Conditions
- Nausea and Vomiting, Chemotherapy-Induced
- Interventions
- First Posted Date
- 2008-01-25
- Last Posted Date
- 2018-01-17
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 710
- Registration Number
- NCT00601172
- Locations
- 🇸🇰
GSK Investigational Site, Poprad, Slovakia
Efficacy And Safety Of GW642444M Comparing Placebo In Adolescent And Adult Subjects With Persistent Asthma.
- Conditions
- Asthma
- Interventions
- Drug: GW642444MDrug: Placebo
- First Posted Date
- 2008-01-24
- Last Posted Date
- 2016-12-16
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 614
- Registration Number
- NCT00600171
- Locations
- 🇹🇭
GSK Investigational Site, Khon Kaen, Thailand
To Assess the Excretion Balance and Pharmacokinetics of a Single Oral Dose of [14C]GW856553 in Healthy Adult Males
- First Posted Date
- 2008-01-24
- Last Posted Date
- 2017-08-04
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 6
- Registration Number
- NCT00599612
- Locations
- 🇬🇧
GSK Investigational Site, Edinburgh, United Kingdom
Intussusception Surveillance After Rotarix Introduction in Mexico
- Conditions
- Intussusception (IS)Rotavirus Vaccines
- Interventions
- Other: Hospital log review.
- First Posted Date
- 2008-01-16
- Last Posted Date
- 2012-03-19
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 786
- Registration Number
- NCT00595205
- Locations
- 🇲🇽
GSK Investigational Site, Mexico Df, Mexico
Open-Label, Placebo-Controlled, Parallel Group Study in Healthy Volunteers to Evaluate the Effects of Two Single MT 400 or Naproxen Sodium Tablets
- First Posted Date
- 2008-01-16
- Last Posted Date
- 2015-04-16
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 42
- Registration Number
- NCT00596245
- Locations
- 🇺🇸
Matthew M. Medlock, MD, Austin, Texas, United States
Pharmacovigilance Study To Evaluate Safety Of AVODART In Subjects With Benign Prostate Hyperplasia
- Conditions
- Benign Prostatic Hyperplasia
- First Posted Date
- 2008-01-15
- Last Posted Date
- 2008-10-15
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 1000
- Registration Number
- NCT00593593
A Randomized Study to Compare the Safety and Immunogenicity of Fluviral® Made With New Versus Aged Bulk
- Conditions
- Influenza Vaccines
- Interventions
- Biological: Fluviral
- First Posted Date
- 2008-01-04
- Last Posted Date
- 2019-06-27
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 1000
- Registration Number
- NCT00586469
- Locations
- 🇨🇦
GSK Investigational Site, Quebec, Canada